Journal of Neuro-Oncology

, Volume 131, Issue 1, pp 185–191 | Cite as

Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastoma

  • Surasak Phuphanich
  • Jeffrey Raizer
  • Marc Chamberlain
  • Paola Canelos
  • Rajesh Narwal
  • Shengyan Hong
  • Robert Miday
  • Minal Nade
  • Kevin Laubscher
Clinical Study


MEDI-575, an immunoglobulin G2κ monoclonal antibody, selectively binds to platelet-derived growth factor-α receptor (PDGFR-α) with high specificity. This multicenter, single-arm, open-label, phase II study evaluated the efficacy and safety of MEDI-575 in patients with recurrent glioblastoma. Adults with first recurrence of glioblastoma following surgery, temozolomide, and radiation received MEDI-575 25 mg/kg intravenously over 60 min every 21 days until disease progression or unacceptable toxicity. Six-month progression-free survival rate (PFS-6) was the primary end point; secondary measures included response rate, overall survival (OS), and safety/tolerability. PDGFR-α expression was evaluated by immunohistochemistry. Fifty-six patients were enrolled; median age was 56.5 years (range 23–79), 66 % were male, and 66 % were aged ≥65 years. PFS-6 was 15.4 % [90 % confidence interval (CI) 8.1–24.9]. No complete or partial responses were observed; 23 (41.1 %) patients had stable disease as best response. Median PFS was 1.4 months (90 % CI 1.4, 1.8); median OS was 9.7 months (90 % CI 6.5, 11.8). The most common treatment-related adverse events (AEs) were diarrhea (16 %), nausea (13 %), and fatigue (13 %). Twelve (21 %) patients reported grade ≥3 AEs, with hydrocephalus (n = 3), dysphagia (n = 2), and convulsion (n = 2) reported in more than 1 patient. Two patients had treatment-related Grade ≥3 AEs of decreased lymphocyte count and asthenia (n = 1 each). Seven patients (13 %) discontinued MEDI-575 owing to AEs. Labeling of PDGFRα in glioblastoma cells and tumor-associated stromal cells was highly variable, with no correlation with PFS. MEDI-575, although well tolerated, had limited clinical activity in recurrent glioblastoma.


Anti-PDGFR-α Monoclonal antibody Progression-free survival Safety Treatment outcomes 



The authors thank the patients and physicians who participated in this study. They also thank Amy Zannikos, PharmD, of Peloton Advantage for medical writing and editorial support, which were funded by MedImmune.


This study was sponsored by MedImmune. Medical writing and editorial support were provided by Amy Zannikos, PharmD, at Peloton Advantage and were funded by MedImmune. No author received an honorarium or other form of financial support related to the development of this manuscript.

Compliance with ethical standards

Conflict of interest

S. Phuphanich and M. Chamberlain report no conflicts to disclose. J. Raizer has received research support from MedImmune and has served on an advisory board, without compensation, for MedImmune. P. Canelos, R. Narwal, S. Hong, R. Miday, M. Nade, and K. Laubscher are employees of MedImmune.


  1. 1.
    Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C, Barnholtz-Sloan JS (2013) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol 15(Suppl 2):ii1–ii56CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466CrossRefPubMedGoogle Scholar
  3. 3.
    Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, Holland E (2009) Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 4:e7752CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Doucette T, Rao G, Rao A, Shen L, Aldape K, Wei J, Dziurzynski K, Gilbert M, Heimberger AB (2013) Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. Cancer Immunol Res 1:112–122CrossRefPubMedGoogle Scholar
  5. 5.
    Westermark B (2014) Platelet-derived growth factor in glioblastoma—driver or biomarker? Ups J Med Sci 119:298–305CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westermark B, Nister M (1992) Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 52:3213–3219PubMedGoogle Scholar
  7. 7.
    Martinho O, Longatto-Filho A, Lambros MB, Martins A, Pinheiro C, Silva A, Pardal F, Amorim J, Mackay A, Milanezi F, Tamber N, Fenwick K, Ashworth A, Reis-Filho JS, Lopes JM, Reis RM (2009) Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas. Br J Cancer 101:973–982CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, Ali IU (1992) Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 52:4550–4553PubMedGoogle Scholar
  9. 9.
    Ozawa T, Brennan CW, Wang L, Squatrito M, Sasayama T, Nakada M, Huse JT, Pedraza A, Utsuki S, Yasui Y, Tandon A, Fomchenko EI, Oka H, Levine RL, Fujii K, Ladanyi M, Holland EC (2010) PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev 24:2205–2218CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Laing N, McDermott B, Wen S, Yang D, Lawson D, Collins M, Reimer C, Hall PA, Andersen H, Snaith M, Wang X, Bedian V, Cao ZA, Blakey D (2013) Inhibition of PDGFR-alpha by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer. Mol Pharmacol 83:1247–1256CrossRefPubMedGoogle Scholar
  11. 11.
    Becerra CR, Conkling P, Vogelzang N, Wu H, Hong S, Narwal R, Liang M, Tavakkoli F, Pandya N (2014) A phase I dose-escalation study of MEDI-575, a PDGFRalpha monoclonal antibody, in adults with advanced solid tumors. Cancer Chemother Pharmacol 74:917–925CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, DeGroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972CrossRefPubMedGoogle Scholar
  13. 13.
    Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572–2578PubMedGoogle Scholar
  14. 14.
    Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740CrossRefPubMedGoogle Scholar
  15. 15.
    Chamberlain MC, Johnston SK (2010) Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J Neurooncol 96:259–269CrossRefPubMedGoogle Scholar
  16. 16.
    Batchelor TT, Grossman SA, Mikkelsen T, Ye X, Desideri S, Lesser GJ (2011) Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology 76:929–930CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Lampson LA (2011) Monoclonal antibodies in neuro-oncology: Getting past the blood–brain barrier. MAbs 3:153–160CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Mehta AI, Brufsky AM, Sampson JH (2013) Therapeutic approaches for HER2-positive brain metastases: circumventing the blood–brain barrier. Cancer Treat Rev 39:261–269CrossRefPubMedGoogle Scholar
  19. 19.
    Reardon DA, Dresemann G, Taillibert S, Campone M, van den Bent M, Clement P, Blomquist E, Gordower L, Schultz H, Raizer J, Hau P, Easaw J, Gil M, Tonn J, Gijtenbeek A, Schlegel U, Bergstrom P, Green S, Weir A, Nikolova Z (2009) Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer 101:1995–2004CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Dresemann G, Weller M, Rosenthal MA, Wedding U, Wagner W, Engel E, Heinrich B, Mayer-Steinacker R, Karup-Hansen A, Fluge O, Nowak A, Mehdorn M, Schleyer E, Krex D, Olver IN, Steinbach JP, Hosius C, Sieder C, Sorenson G, Parker R, Nikolova Z (2010) Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J Neurooncol 96:393–402CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Surasak Phuphanich
    • 1
    • 5
  • Jeffrey Raizer
    • 2
  • Marc Chamberlain
    • 3
  • Paola Canelos
    • 4
  • Rajesh Narwal
    • 4
  • Shengyan Hong
    • 4
  • Robert Miday
    • 4
  • Minal Nade
    • 4
  • Kevin Laubscher
    • 4
  1. 1.Johnnie L. Cochran Jr. Brain Tumor CenterCedars-Sinai Medical CenterLos AngelesUSA
  2. 2.Northwestern Brain Tumor InstituteNorthwestern UniversityChicagoUSA
  3. 3.University of WashingtonSeattleUSA
  4. 4.MedImmuneGaithersburgUSA
  5. 5.Department of Neurology, Division of Neuro-OncologyBarrow Neurological InstitutePhoenixUSA

Personalised recommendations